Guide

Clinical investigator selection

Clinical investigator selection is the sponsor’s obligation to choose, for each trial site, a physician qualified by training and experience to conduct the study — and to be able to show how that judgment was made. It is a regulatory duty (21 CFR 312.53), a GCP expectation (ICH E6), and the point in a trial where the most consequential decisions are still cheap to change.

What the regulations require

Under 21 CFR 312.53, a sponsor “shall select only investigators qualified by training and experience as appropriate experts to investigate the drug.” Before a clinical investigator may begin, the sponsor must obtain a signed Form FDA 1572, a curriculum vitae or other statement of qualifications, an outline of the study protocol, and the financial-disclosure information the marketing application will later need. The same section requires the sponsor to select monitors who are qualified by training and experience to monitor the investigation.

ICH E6 (Good Clinical Practice) states the same responsibility in international terms: the sponsor selects clinical investigators who are qualified by training and experience and have adequate resources to conduct the trial properly, and it places the trial’s data quality with the sponsor regardless of who was selected. FDA’s broader statement of sponsor duties — selecting qualified investigators, giving them the information they need, monitoring the investigation, and ensuring it is conducted according to the plan — is in 21 CFR 312.50; see sponsor responsibilities for clinical investigators.

What “qualified” is usually read to mean. Credentials, licensure, therapeutic-area experience, a site that can run the protocol, and enough eligible patients. All true. But a clinical investigator FDA has inspected, cited, sent a warning letter, or moved to disqualify is also a fact about qualification — and it is a fact a sponsor is better placed to defend having checked than having missed.

The criteria sponsors and CROs use in practice

Most selection processes weigh some version of these, in roughly this order:

1. Therapeutic and protocol fit. Experience in the indication and phase; familiarity with the assessments the protocol demands.

2. Patient access and enrollment history. The eligible population the site can actually reach, and how the clinical investigator enrolled on comparable studies — screen-failure rates, retention, time to first patient.

3. Site capability. Staff, facilities, equipment, drug storage, source-document practices, competing studies, and the clinical investigator’s own availability — usually assessed at a site qualification visit.

4. Prior performance with this sponsor or CRO. Query rates, protocol deviations, monitoring-visit findings, audit outcomes.

5. Regulatory history. Whether FDA has inspected the clinical investigator before and how each inspection was classified, what was cited, whether a warning letter followed, and whether the investigator appears in disqualification proceedings or on the debarment list. This is the check most often done as a single warning-letter search — see below.

6. Financial and legal. Financial-disclosure exposure (21 CFR part 54), debarment certification, contract and budget terms.

Where the FDA record fits — and the check most selections stop at

Many diligent quality teams check FDA’s public warning-letter page when a site is proposed. That is a sensible check, and a warning letter is a serious mark. But there is a lot more to inspection history than a warning letter. FDA classifies every clinical investigator inspection it closes — No Action Indicated, Voluntary Action Indicated, or Official Action Indicated, the most serious inspection classification FDA assigns. Most records with a story to tell never reach a warning letter at all.

Two features of the system make this the sponsor’s problem to solve rather than something that will arrive on its own. FDA sends inspection findings to the clinical investigator, not typically to the sponsor. And a large site often runs several sponsors’ trials concurrently, so an inspection — and whatever it found — may have concerned another sponsor’s study entirely. “Nobody mentioned it” is a real possibility, not an accusation. The practical answer is to read the whole record before selection: that is clinical investigator vetting, the record part of the selection file.

Documenting the selection decision

An inspector or auditor who asks “why this site?” is asking for a file, not a recollection. The file should show what was checked, on what date, and what it showed — including a check that found no record. For the regulatory-history check, that means the inspection history with each classification, the findings, any warning letter, and the disqualification and debarment screens, with the date they were run. A site score from a selection platform cannot go in that file; a documented record can.

Where a record shows findings, the sponsor has three options, in this order: ask the site for their responses and corrective action plans; visit the site before signing; or choose a site without this history. Any of the three is defensible when it is written down. Discovering the history after activation is not.

Selection is not a one-time event

FDA classifies an inspection weeks to months after it closes, and a site selected with no findings on record can be inspected during the trial. 21 CFR 312.56 expects the sponsor to monitor the investigation and to act on a clinical investigator’s non-compliance. Re-screening the roster periodically — at least against the disqualification and debarment lists, ideally against the full record — is how the selection decision stays true for the life of the study.

Questions this page answers

What is clinical investigator selection?

It is the process a trial sponsor (or a CRO acting for one) uses to choose the physicians who will conduct a clinical trial at each site. Under 21 CFR 312.53 the sponsor must select only clinical investigators qualified by training and experience; ICH E6 states the same expectation. In practice it combines therapeutic fit, enrollment capacity, site capability, prior performance and regulatory history.

What is the difference between site selection and clinical investigator selection?

They overlap almost completely. “Site selection” is the operational term (facilities, staff, patient population, budget); “clinical investigator selection” is the regulatory term, because the obligation in 21 CFR 312.53 attaches to the person who signs the Form FDA 1572. A site is selected by selecting its investigator.

Does FDA tell a sponsor when it inspects one of its clinical investigators?

FDA sends inspection findings to the clinical investigator, not typically to the sponsor. The investigator is not required to tell the sponsor either, unless a quality agreement between them says so. Sponsors are formally notified when an investigator is disqualified, which is the end of a process, not the beginning.

Is checking for a warning letter enough?

It is a good check, and a warning letter is a serious mark, but it is the last rung of a ladder. FDA classifies every inspection, and most records with a history never reach a warning letter. Reading the inspection history, classifications and findings is the fuller check.

How should the selection decision be documented?

As a dated file: what was checked, when, and what it showed, including a check that found no record. For the regulatory-history part, that means the inspection history and classifications, the findings, any warning letter, and the disqualification and debarment screens with the date they were run.

Check a name now, free. Screen a clinical investigator against FDA’s disqualification proceedings and debarment list. No account needed.

Run a free status check

Want the inspection record behind it? Inspections, findings and warning letters, benchmarked. Subscriptions start at $249 a month; access is immediate.

See a sample report See plans

About this guide. It is educational, and it is not regulatory or legal advice. The authorities are the Code of Federal Regulations, FDA’s guidance and ICH E6; where this guide and those sources differ, the sources govern.